Zobrazeno 1 - 10
of 10
pro vyhledávání: ''
Autor:
Priscilla Nardi, Rocco Pasqua, Chiara Fratini, Girolami M, Carla Giordano, Giulio Illuminati, Fabio Carboni
Background/aim Primary adrenal lymphoma (PAL) is rare and aggressive. The aim of this retrospective study was to compare the results of surgery and chemotherapy compared to chemotherapy alone for the treatment of this condition. Patients and methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f5c7c5245f3e86a67758ca543b98fd6
http://hdl.handle.net/11573/1546617
http://hdl.handle.net/11573/1546617
Autor:
Ondrej Sorejs, Petr Hosek, Vaclav Liska, Pavel Pitule, Ondrej Vycital, Diana Maceckova, Ondrej Topolcan, Jindrich Finek, Radek Kucera, Ondrej Fiala, Jan Bruha
Publikováno v:
Cancer Genomics Proteomics
PubMed Central
Cancer Genomics-Proteomics
PubMed Central
Cancer Genomics-Proteomics
Background/Aim: MicroRNAs (miRs) play an important role in the regulation of cancer-related processes and are promising candidates for cancer biomarkers. The aim of the study was to evaluate the association of response to anti-EGFR monoclonal antibod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad82886f2e43e22fda2ef58fa5c30e40
https://europepmc.org/articles/PMC7472450/
https://europepmc.org/articles/PMC7472450/
Publikováno v:
Cancer Genomics Proteomics
Background/aim Circulating tumor DNA (ctDNA) bears specific mutations derived from tumor cells. The amount of mutant ctDNA may reflect tumor burden. In this study, we detected epidermal growth factor receptor (EGFR) mutations in ctDNA as a monitoring
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::361f196c5e413f71c2515bd8e822226c
https://europepmc.org/articles/PMC7367604/
https://europepmc.org/articles/PMC7367604/
Background/aim Previous research has suggested that patients with metastatic renal cell cancer (mRCC) and bone metastases have a poorer prognosis compared to their counterparts with no skeletal involvement. Therefore, we analyzed the management and o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::774d57452ec8ad273e8a3eeda2d60ae9
https://europepmc.org/articles/PMC7157836/
https://europepmc.org/articles/PMC7157836/
Autor:
Mariko Kamiya, Masaaki Murakawa, Satoshi Kobayashi, Norio Yukawa, Hiroshi Tamagawa, Makoto Ueno, Naoto Yamamoto, Manabu Morimoto, Yasushi Rino, Toru Aoyama, Yosuke Atsumi, Yuto Kamioka, Munetaka Masuda, Soichiro Morinaga
Background: The C-reactive protein (CRP)-to-serum albumin ratio is associated with a poor prognosis in patients with several cancers. The purpose of this study was to clarify the relationship between the preoperative CRP/Alb ratio and overall surviva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::170cb2d9bf9f11ceb02825bca8b3d85d
https://europepmc.org/articles/PMC6984104/
https://europepmc.org/articles/PMC6984104/
Background/aim Hepatic arterial infusion chemotherapy (HAIC) is a treatment option for metastatic breast cancer (MBC) patients with extensive liver metastasis (LM); however, the appropriate regimen and the treatment effects have not been discussed. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2de51ecc0e809fb7a5587b22613d20ce
https://europepmc.org/articles/PMC6984114/
https://europepmc.org/articles/PMC6984114/
Background Laryngeal stenosis is challenging for treatment due to uncertain etiology. Primary laryngeal lymphoma as the initial clinical manifestation of laryngeal stenosis has been rarely reported. Primary diffuse large B-cell lymphoma as an underly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe86bab757bc381429a51ab2dbba7829
https://europepmc.org/articles/PMC6984083/
https://europepmc.org/articles/PMC6984083/
Background Immune checkpoint inhibitors are indicated for non-small cell lung cancer (NSCLC) and head and neck cancer, and combined treatment of immune checkpoint inhibitor and chemotherapy has recently been carried out in patients with NSCLC. Howeve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::392bf8a7a3dab245e5fee884eedca7e6
https://europepmc.org/articles/PMC6984065/
https://europepmc.org/articles/PMC6984065/
Autor:
Asato Otsubo, Yasuyoshi Miyata, Kojiro Ohba, Tsutomu Yuno, Tomohiro Matsuo, Yuta Mukae, Kensuke Mitsunari, Kyohei Araki, Hideki Sakai, Yuichiro Nakamura
Background/Aim: Immune check-point inhibitors are often unsuitable for patients with urothelial cancer with a poor performance status (PS 2 or 3). The aim of this study was to assess the safety and usefulness of combined therapy with low-dose gemcita
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4861375b1dcc37590a43c8c6cd8f5bf6
https://europepmc.org/articles/PMC6899086/
https://europepmc.org/articles/PMC6899086/
Feasibility of Neoadjuvant FOLFOX Therapy Without Radiotherapy for Baseline Resectable Rectal Cancer
Autor:
Michihiro Koizumi, Kohki Takeda, Goro Takahashi, Takuma Iwai, Keisuke Hara, Takeshi Yamada, Yasuyuki Yokoyama, Eiji Uchida, Seiichi Shinji, Keiichiro Ohta, Hiroshi Yoshida
Background/aim The combination of oxaliplatin, leucovorin and fluorouracil (FOLFOX) has been established as postoperative adjuvant chemotherapy for stage III colon cancer. However, the safety and efficacy of neoadjuvant FOLFOX in patients with rectal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::812d0d166d31fe4345aca0c6d5d7f140
https://europepmc.org/articles/PMC6117778/
https://europepmc.org/articles/PMC6117778/